Therapeutic effect of long-term melatonin treatment on the course and fatal outcome of modeled acute radiation sickness.
We studied the effect of long-term administration of melatonin to male C57Bl/6 mice starting from day 3 after whole-body γ-irradiation (9.5-10.0 Gy, 7.7-17.1 cGy/min). It was found that replacement of drinking water with melatonin solution (5 mg/liter) did not reduce the amount of fluid intake throughout the period of acute radiation injury. The daily dose of melatonin was 0.9-1.2 mg/kg body weight (this parameter was lower at the peak of the disease and increased during the recovery stage). Melatonin by more than 20% (p<0.05) improved survival of mice exposed to γ-irradiation in a dose of LD97/30, reduced leukopenia during the stage of acute manifestations of the disease and maximum mortality, and increased blood leukocyte count by 40% (p<0.05) by day 12 after irradiation.
State Research Center of the Russian Federation, Institute of Biomedical Problems, Russian Academy of Sciences, Moscow, Russia, mikhail-v-vasin@yandex.ru.
M V
MV
Vasin
I B
IB
Ushakov
V Yu
VY
Kovtun
L A
LA
Semenova
L V
LV
Koroleva
A A
AA
Galkin
R V
RV
Afanas'ev
D054508:Acute Radiation Syndrome / Q000188:drug therapy* / Q000401:mortality; D000818:Animals; D000975:Antioxidants / Q000627:therapeutic use*; D005720:Gamma Rays / Q000009:adverse effects; D007958:Leukocyte Count; D008297:Male; D008550:Melatonin / Q000627:therapeutic use*; D051379:Mice; D008810:Mice, Inbred C57BL; D011837:Radiation-Protective Agents / Q000627:therapeutic use*; D014916:Whole-Body Irradiation / Q000009:adverse effects
D000975:Antioxidants; D011837:Radiation-Protective Agents; D008550:Melatonin